Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00805129 · ClinicalTrials.gov registry record · Phase 2
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00805129: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00805129 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00805129, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to learn what effects, good and/or bad, Everolimus has on advanced urothelial cancer. The goal of this clinical research study is to learn if the study drug Everolimus can shrink or slow the growth of urothelial cancer. The safety of this drug will also be studied. The patients physical state, changes in the size of the tumor, and laboratory findings taken while on-study will help us decide if Everolimus is safe and effective.
Interventions
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-12-05 |
| Est. Completion | 2021-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00805129
The ClinicalTrials.gov registry entry for NCT00805129 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Everolimus is the first listed.
NCT00805129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00805129 about?
NCT00805129 is a clinical study titled "Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium". The purpose of this study is to learn what effects, good and/or bad, Everolimus has on advanced urothelial cancer. The goal of this clinical research study is to learn if the study drug Everolimus can shrink or slow the growth of urothelial cancer. The safety of this drug will also be studied. The ...
What is the current status of trial NCT00805129?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2008-12-05. Estimated completion is 2021-12-15.
What interventions are being tested in trial NCT00805129?
The interventions under investigation include: Everolimus (DRUG).
Who is sponsoring clinical trial NCT00805129?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.